عنوان

بررسی تأثیر ممانتین به عنوان درمان کمکی در بهبود علایم منفی و شناختی دربیماران مبتلا به اسکیزوفرنی مداوم یک کارآزمایی بالینی تصادفی دوسو کور

Text of Note

Objective: The objective of this study was to assess the efficacy of Memantine as add onto Risperidone for treatment of negative and cognitive symptoms in schizophrenic patients with long duration:a randomized double blind study Method: This study was a 12 week randomized double blind study with placebo control that was registered in Iranian Registry of Clinical Trials (IRCT24817) in Razi Psychiatry Hospital, Tehran, Iran. 46 Male patients with schizophrenia according to DSM-IV-TR criteria aged between 18-55, their antipsychocotic drugs changed to Risperidone 10-20 mg per day. After 3 to 4 weeks, in maintenance phase of treatment, they were randomized to receive either Capsule of Memantine (20 mg/day)twice a day or placebo with the same shape. Cognitive, positive, negative and general symptoms have been assessed in baseline and weeks 6 and 12 of the treatment with MMSE & BPRS. Data were analyzed with t-test in SPSS-21. Results: There were significant changes in cognetive symptoms in MMSE score after 6 week treatment with Memantine (P<0.01) and in negative symptoms after 12 week treatment (P<0.01),But no statically significant differences were observed after 12 week treatment in positive and general psychopathologic symptoms scale. Conclusion: according to our study Memantine has significant improvement in cognitive and negative symptoms of schizophrenic patients as an adjunctive to Risperidone compared to placebo after 12 week but It doesnt change positive and general psychopathologic symptoms. neither age, duration of illness, family history were not statistically significant in efficacy of Memantine. Key words: Memantine, Schizophrenia, cognitive symptoms , negative symptoms

ba